Advanced Accelerator Applications  

United States
  • Booth: 8

Advanced Accelerator Applications (NASDAQ:AAAP) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA’s lead therapeutic product candidate, Lutathera®, is a novel MNM compound that AAA is currently developing for the treatment of Neuroendocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France and opened it US headquarters in New York in 2012.